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HIV origins in Non Human Primates
 Several cross-species
transmissions from
Non-Human Primates
 2 types
 13 groups
SIVsm
SIVcpzSIVgor
Finding the Simian Ancestors of 
HIV-1
 Sampling wild living
Non Human Primates
 Identifying those SIV-
infected
 Comparing the 
genetic sequence of 
these SIV to that of 
HIV
SIV HIV
?
Group N
Group M
Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1
Brandon F. Keele Science 2006
Origin of the HIV-1 group O epidemic in western
lowland gorillas
Mirela D’arc PNAS 2015
Group O
Group P
Mapping the Simian Ancestors of 
HIV-1
SIVgor > group O
SIVgor > group P
SIVcpz > group M
SIVcpz > group N
Four groups, one pandemic
 Group M : pandemic, tens of millions 
infections worldwide
 Group P : 2 cases identified to date
 Group N : 15 cases identified to date
 Group O : endemic in Cameroon
(10,000 to 30,000)
Intrinsic properties – viral fitness
Virus – Host Interactions
Restriction factors
Viral adaptation to its host: 
consequences?
 Replication rate
 Viral load (viremia)
HIV-2 < HIV-1
 Pathogenicity (progression to AIDS)
 Transmission rate (Hum to Hum)
 Spread?
HIV-2 > HIV-1 group O
Many factors, many scales
 Intrinsic viral 
factors
 Host factors
 At risk behaviours
 Epidemiological
context
 … and more!!!
HIV-1 Group O : Epidemiology
 Endemic in Cameroon: 1% of HIV+ samples
 1,1% of 7.030 HIV+ samples from Yaounde, 2009 - 2010 
 1,0% of 1.469 HIV+ samples from Yaounde, 1996 - 2001
HIV-1 Group O : Epidemiology
 Drop of relative Group O prevalence among
HIV+ samples in the early 1990’s
Group O 
relative 
prevalence
among HIV+ 
samples
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HIV-1 Group O : Epidemiology
 Also found in some geographically or 
historically linked countries 
HIV-1 Group O : Epidemiology
 Oldest HIV-1 group O infection ever
reported: Norway in the 1960’s 
 In France: 142 patients identified since 1992 
 Survey network : RES-O
Group O infections: diagnosis, follow up 
and treatment?
 High divergence between HIV-1/M and 
HIV-1/O
 Assays designed to detect group M can
be less sensitive
 Impact on serodiagnosis and viral load
quantitation
Group O infections: diagnosis, follow
up and treatment?
 Non-specific tools: group O is detected but 
not identified as such
 No specific algorithm available for 
interpretation of resistance mutations
 Natural presence of the Y181C mutation in 
the Reverse Transcriptase 
 Confers resistance to the 1st generation NNRTIs
Reverse transcriptase
NNRTI
NRTI
INI
PI
EI
FI
HIV-1 Group O Diversity and 
Evolution
 What evolution dynamics?
 What factors involved?
 No exhaustive sequential testing
 No prevalence data before the 1980’s
Data, tools, and hypotheses
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Group O genetic diversity: 
background
 Several nomenclature proposals
 Yamaguchi: 5 clusters
 Roques: 3 clades
 Few sequences available
 > 10 year old studies
HIV-1 Group O
Roques et al., 2002 (env gp41)
HIV-1 Group O
Yamaguchi et al., 2002 (env gp160)
HIV-1 Group M
Archer et al., 2007 (env gp160)
Group O tMRCA: background
 Most Recent Common Ancestor (MRCA) estimated to 
have existed around 1920 (1890 – 1940)
Group O tMRCA: background
 Most Recent Common Ancestor (MRCA) in 
1920 does not mean crossing the barrier
species in 1920
1920
Group O tMRCA: background
 Most Recent Common Ancestor (MRCA) in 
1920 rather means crossing the barrier
species in 1920 or before
19201800
Group O tMRCA: background
19201800 1840
Group O tMRCA: background
19201800 1840
???
Group O dynamics: background
t1 t2 t3 t4 t5
x2 x2 x2 x2
Exponential growth
t1 t2 t3 t4 t5
x2 x2x2 x2
Viral population dynamics?
Group O dynamics: background
 ‘The effective number of Group O infections has been 
increasing exponentially with a slower growth rate 
than group M’
Objectives of the study
 Use the largest series of HIV-1/O 
sequences to:
 Investigate HIV-1/O genetic diversity in 
France and in Cameroon
 Compare and evaluate the previous
nomenclature systems
 Re-estimate the tMRCA of HIV-1/O
 Investigate the dynamics of HIV-1/O 
genetic diversity over time
 Study the phylogenetic distribution of 
the Y181C resistance mutation
Methods
 Samples from 190 patients 
 Time of sampling ranging from year 1987 to 2012
 In France Cameroon Gabon
(N=102) (N=87) (N=1)
 Sanger sequencing in three genome regions
 Concatenated sequences submitted to:
 Phylogenetic analyses (Maximum Likelihood)
 Evolutionary analyses (Bayesian inference)
Results: Country distribution
 Sequences sampled in France or in 
Cameroon are phylogenetically
interspersed: 
 Continuous strain importations from
Cameroon to France rather than local 
epidemic
Sampling country:
Cameroon
France
Results: Topology & Nomenclature
 A continuum of diversity with few clusters
 An asymetrical shape (comet vs HIV-1/M double 
star)
 The previous nomenclatures were partially discordant but 
already shown a predominant clade (A or I : blue)
Ib
Ia
A1
A2
A3
B
C
II
III
IV
V
Iu
Roques et al., 2002 (env gp41) Yamaguchi et al., 2002 (env gp160) HIV-1/M
Results: MRCA new estimates
 Dataset = 157 concatenated sequences with a 
single known sampling time for the 3 regions
 Several growth models tested gave consistent 
estimates
 HIV-1/O MRCA around 1930 (95% HPD: 1914 – 1944)
 Predominant clade MRCA around 1945 (1933 – 1955)
Results: Population Dynamics
 2 phases of fast exponential growth of 
HIV-1/O genetic diversity
 First one in the 1950’s
 Second one, more extensive, in the 1980’s
Results: Population Dynamics
 What factors involved?
 ‘Parenteral infection on the occasion of mass 
medical campaigns during the 1920 to 1960 
period is the most likely explanation’
Results: Population Dynamics
 The predominant
clade (blue) only
displays the 2nd 
fast growth phase
 The predominant
clade emerged in 
the 1980’s from a 
now minor
population 
(orange)
Group O predominant clade only
Overall Group O
Results: Distribution of the Y181C 
mutation in the RT
 Confers natural resistance to the Non Nucleotide
Reverse Transcriptase Inhibitors (NNRTIs)
 Found in 62,5% sequences sampled from NNRTI-
naive patients
 Statistically associated to the predominant clade
Residue in 80 
NNRTI-naive
patients:
181Y
181C/Y
181C
Results: Distribution of the Y181C 
mutation in the RT
From Rural to Urban areas?
???
Slowing down again
Group O relative 
prevalence
among HIV+ 
samples
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Take home messages
 Group O MRCA estimated
in 1920 - 1930
 Close to Group M 
 Despite limited spread, 
group O growth had been 
through slow and fast
phases
 Intrinsic as well as 
contextual factors might
have been involved
To conclude
 Don’t forget wise Socrates…
 Sampling still limited
 Need for a more exhaustive study in Cameroon
To conclude
 Let’s put a little philo in our phylo 
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